Movember substudy
- Conditions
- matastasized castrate resistent prostate cancer
- Registration Number
- NL-OMON26162
- Lead Sponsor
- VU university Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
Patients with mCRPC eligible for the GAP2-FDHT study
- Written informed consent
Exclusion Criteria
- Claustrophobia
- Multiple malignancies
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A pharmacokinetic model for [18F]FDHT; an appropriate simplified quantitative method for [18F]FDHT; concordance of DCE-MRI and [15O]-water parameters.
- Secondary Outcome Measures
Name Time Method not apllicable